Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +9.88% and +6.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, July 21, 2026 NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...
PR Newswire
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results...
Yahoo! Finance: News
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.read more...
Benzinga
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $137.00 at Royal Bank Of Canada
Royal Bank Of Canada increased their price objective on shares of Rhythm Pharmaceuticals from $136.00 to $137.00 and gave the company an "outperform" rating in a research report on Wednesday...
MarketBeat
Wells Fargo & Company Boosts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $144.00
Wells Fargo & Company boosted their price target on Rhythm Pharmaceuticals from $143.00 to $144.00 and gave the stock an "overweight" rating in a research note on Wednesday...
MarketBeat
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday
Key PointsThe biotech was in the headlines recently after the FDA approved a new indication for its single commercialized drug...
Nasdaq News: Markets

Advertisement|Remove ads.